Microbiome-Targeted Therapeutics In Immunology

Flares in gastrointestinal and dermatology indications are characterized by a shift in the proportion of bacterial species in either the gut or skin microbiome. This report focuses on the development of therapies targeting the skin microbiome for the treatment of acne, atopic dermatitis and psoriasis and on the development of therapies targeting the gut microbiome for the treatment of Crohn’s disease, ulcerative colitis, and irritable bowel syndrome.

Scope

GlobalData’s Microbiome-Targeted Therapeutics in Immunology combines key opinion leader and payer insight with in-house analyst expertise to provide an insight-rich look at the microbiome space in immunology.

Components of the report include:

• Overview of the Gut and Skin Microbiome – microbial dysbiosis by indication

• Epidemiology Overview – prevalent or diagnosed prevalent cases by indication for the 16MM

• Pipeline Assessment—promising late-stage products and early-stage pipeline by indication

• Key Players – leading industry companies by indication

• Clinical Trials Mapping and Design — trial breakdown by phase/indication and trial design by indication

• Fecal Microbiota Transplants—opportunities and challenges for gastrointestinal indications

• Pricing, Reimbursement and Regulatory Strategy – US payer perspective on late-stage therapies

• Market Outlook — market potential estimation of late-stage therapies and key launch dates

Reasons to buy

Develop business strategies by understanding the trends shaping and driving the global microbiome market in immunology.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Gain insights to help plan and design your clinical trials.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Identify key pricing and reimbursement strategies.

Companies mentioned

Qu Biologics

Synthetic Biologics

4D Pharma

Enterome Bioscience

Second Genome

Seres Therapeutics

Rebiotix

Intrexon

Vedanta Biosciences

AOBiome

Matrisys Bioscience

SFA Therapeutics

Table of Contents

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2 Executive Summary

2.1 Key Findings

2.2 KOL and Payer Insight on Microbiome Competitive Landscape

3 Overview of the Gut and Skin Microbiome

3.1 Microbiome of the Skin

3.2 Microbiome in Atopic Dermatitis

3.3 Microbiome in Acne

3.4 Microbiome in Psoriasis

3.5 Microbiome of the Gut

3.6 Microbiome in Inflammatory Bowel Disease

3.7 Microbiome in Irritable Bowel Syndrome

4 Epidemiology Analysis

4.1 Epidemiology Analysis – Acne Vulgaris

4.2 Epidemiology Analysis – Atopic Dermatitis

4.3 Epidemiology Analysis – Psoriasis

4.4 Epidemiology Analysis – Crohn’s Disease

4.5 Epidemiology Analysis – Ulcerative Colitis

4.6 Epidemiology Analysis – Irritable Bowel Syndrome

5 Pipeline Assessment

5.1 Overview of the Development of Pipeline Therapies

5.2 Pipeline Assessment – The Gut Microbiome

5.3 Qu Biologics’ QBECO-SSI

5.4 Synthetic Biologics’ SYN-010

5.5 Pipeline Assessment – The Skin Microbiome

5.6 AOBiome’s B-244

5.7 Matrisys Bioscience’s MSB-01

6. Key Players

6.1 Key Players – Companies Targeting the Microbiome

6.2 Analysis of Company Portfolio Gap – Gut Microbiome

6.3 Analysis of Company Portfolio Gap – Skin Microbiome

7 Clinical Trial Mapping and Design

7.1 Clinical Trial Mapping and Design – Gut Microbiome

7.2 Clinical Trial Mapping and Design – Skin Microbiome

8 Fecal Microbiota Transplants

8.1 Is Fecal Microbiota Transplant a Viable Option?

8.2 Clinical Trial Mapping and Design

9 Pricing, Reimbursement, and Regulatory Strategy

9.1 US Strategies for Gastrointestinal Indications

9.2 Payers Perspective on QBECO-SSI

9.3 Payers Perspective on SYN-010

9.4 US Strategies for Dermatology Indications

9.5 Payers Perspective on B-244

9.6 Payers Perspective on MSB-01

10 Market Outlook

10.1 Market Outlook for AOBiome’s B-244

10.2 Market Outlook for Synthetic Biologics’ SYN-010

10.3 Market Outlook for Qu Biologics’ QBECO-SSI

10.4 Key Launch Dates for Pipeline Therapies

11 Appendix

11.1 Sources

11.2 Methodology

11.3 Primary Research

11.4 About the Authors

11.5 About GlobalData

11.6 Contact Us

11.7 Disclaimer

List of Tables

Table 1: Key Findings

Table 2: KOL and Payer Insights on the Microbiome Competitive Landscape

Table 3: The Microbiome in Psoriasis

Table 4: The Microbiome in Irritable Bowel Syndrome

Table 5: Assessment of Pipeline Therapies Targeting the Gut Microbiome

Table 6: QBECO-SSI for Crohn’s disease – Qu Biologics

Table 7: QBECO-SSI for UC – Qu Biologics

Table 8:SYN-010 (lovastatin MR) for IBS-C– Synthetic Biologics

Table 9:Assessment of Pipeline Therapies Targeting the Skin Microbiome

Table 10: B-244 for Acne – AOBiome

Table 11: B-244 for AD – AOBiome

Table 12: MSB-01 for AD – Matrisys Bioscience

List of Figures

Figure 1: Overview – Gut and Skin Microbiome

Figure 2: Microbiome of the Skin

Figure 3: The Microbiome in Atopic Dermatitis

Figure 4: The Microbiome in Acne Vulgaris

Figure 5: The Microbiome in Inflammatory Bowel Disease

Figure 6: Epidemiology Analysis

Figure 7: Epidemiology – Acne Vulgaris

Figure 8: Epidemiology – AD

Figure 9: Epidemiology – PsO

Figure 10:Epidemiology – Crohn’s Disease

Figure 11: Epidemiology – UC

Figure 12: Epidemiology – IBS

Figure 13: Competitive Assessment of Key Players Targeting the Gut and Skin Microbiome

Figure 14: Overview of the Development Pipeline for Therapies Targeting the Gut and Skin Microbiome

Figure 15: Key Players

Figure 16: Key Players in Gastrointestinal Indications

Figure 17: Key Players in Dermatology Indications

Figure 18: Clinical Trial Mapping and Design

Figure 19: Ongoing or Planned Trials for Drugs Targeting the Gut Microbiome

Figure 20: Completed, Ongoing, and Planned Trials for Drugs Targeting the Gut Microbiome

Figure 21: Trials for Drugs Targeting the Skin Microbiome

Figure 22: Completed, Ongoing, and Planned Trials for Drugs Targeting the Skin Microbiome

Figure 23: Fecal Microbiota Transplants

Figure 24: Clinical Trials Assessing FMT in IBD and IBS

Figure 25: Pricing, Reimbursement, and Regulatory Strategy

Figure 26: Average ACOT of Marketed Drug Classes for IBD

Figure 27: Average ACOT of Marketed Therapies for IBS-C

Figure 28: ACOT of Marketed Drug Classes for Acne

Figure 29: ACOT of Marketed Drug Classes for AD

Figure 30: ACOT of Marketed Drug Classes for AD

Figure 31: Market Outlook

Figure 32: Market Potential Estimation in Acne

Figure 33: Market Potential Estimation in IBS-C

Figure 34: Market Potential Estimation in Crohn’s Disease

Figure 35: Key Launch Dates for Pipeline Therapies

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports